Literature DB >> 21151803

Long-term results of cyclosporine-steroid therapy in 131 non-matched cadaveric renal transplants.

Robert D Gordon1, Thomas E Starzl, Thomas R Hakala, Rodney J Taylor, Gerhard P J Schroter, J Thomas Rosenthal, Richard Well, Shunzaburo Iwatsuki, Barbara J Carpenter.   

Abstract

One-hundred-and-twenty-eight recipients of 131 consecutive, non-matched cadaver renal allografts were treated with cyclosporine and steroids. They have been followed for 4 to 6 yr. Cumulative patient survival at 1-yr was 92.2% and at 6yr it is 77.8%. Cumulative graft survival at 1-yr was 79.4% and at 6 yr it is 50.0%. After the high-risk 1st yr, the rate of graft loss was even and similar to that reported after the 1st yr for grafts treated with azathioprine and steroids. This indicates that cyclosporine nephrotoxicity has not had an obvious adverse effect on the survival of chronically functioning grafts. The results were better with primary grafting versus retransplantation, but were not significantly influenced by age, diabetes mellitus, or a delayed switch in patients from cyclosporine to azathioprine. We have concluded that cyclosporine-steroid therapy is safe and effective for long-term use after cadaveric renal transplantation.

Entities:  

Year:  1987        PMID: 21151803      PMCID: PMC3000176     

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  14 in total

1.  Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy.

Authors:  T E Starzl; M A Nalesnik; K A Porter; M Ho; S Iwatsuki; B P Griffith; J T Rosenthal; T R Hakala; B W Shaw; R L Hardesty
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

2.  Clinical kidney transplants.

Authors:  P I Terasaki; G Opelz; M R Mickey
Journal:  Cell Immunol       Date:  1981-08       Impact factor: 4.868

Review 3.  The price of immunotherapy.

Authors:  I Penn
Journal:  Curr Probl Surg       Date:  1981-11       Impact factor: 1.909

4.  Variable convalescence and therapy after cadaveric renal transplantation under cyclosporin A and steroids.

Authors:  T E Starzl; T R Hakala; J T Rosenthal; S Iwatsuki; B W Shaw
Journal:  Surg Gynecol Obstet       Date:  1982-06

5.  Cyclosporine-associated chronic nephropathy.

Authors:  B D Myers; J Ross; L Newton; J Luetscher; M Perlroth
Journal:  N Engl J Med       Date:  1984-09-13       Impact factor: 91.245

6.  Cadaver donor renal transplantation by centers of the South-Eastern Organ Procurement Foundation. The prospective study after 6.5 years and 3811 allografts.

Authors:  J C McDonald; W Vaughn; R S Filo; G Mendez-Picon; G Niblack; E K Spees; G M Williams
Journal:  Ann Surg       Date:  1984-10       Impact factor: 12.969

7.  Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporin treatment: beneficial effect of low doses in early post-transplantation period.

Authors:  G Klintmalm; S O Bohman; B Sundelin; H Wilczek
Journal:  Lancet       Date:  1984-10-27       Impact factor: 79.321

8.  Cyclosporine: five years' experience in cadaveric renal transplantation.

Authors:  R M Merion; D J White; S Thiru; D B Evans; R Y Calne
Journal:  N Engl J Med       Date:  1984-01-19       Impact factor: 91.245

9.  The use of cyclosporin A and prednisone in cadaver kidney transplantation.

Authors:  T E Starzl; R Weil; S Iwatsuki; G Klintmalm; G P Schröter; L J Koep; Y Iwaki; P I Terasaki; K A Porter
Journal:  Surg Gynecol Obstet       Date:  1980-07

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.